Selection Factors for Treatment and Stratification of Rare Abdominal or Pelvic Tumors with Peritoneal Metastases
- 30 July 2022
- journal article
- review article
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 14 (S1) , 7-14
Abstract
To maximize the results of treatments for peritoneal metastases for rare abdominal or pelvic tumors, selection of patients with a possibility for long-term success is necessary. Because these malignancies are rare, data from which these selection factors can be extracted do not exist. In order to facilitate knowledgeable patient selection for treatment, the well established clinical and histopathologic features of the common malignancies treated for peritoneal metastases were reviewed. The potential application of selection factors for common diagnoses was explored in an attempt to provide selection factors for rare tumors. The histopathologic grade, the lymph node status, the Ki-67 proliferation index, prior surgical score (PSS), preoperative radiologic imaging, preoperative laparoscopic assessment, response to neoadjuvant chemotherapy, peritoneal cancer index (PCI), and completeness of cytoreduction score were all included in this search for relevant selection factors for a rare disease. To facilitate the use of selection factors from common peritoneal metastases diagnoses, these diseases were divided into four groups. Placement of the rare cause of peritoneal metastases into one of these four groups will allow knowledgeable selection for treatment. Rare diseases with a natural history resembling low-grade appendiceal neoplasms are in group 1, diseases resembling lymph node negative colorectal cancer are in group 2, diseases resembling lymph node positive colorectal peritoneal metastases in group 3, and diseases resembling gastric cancer in group 4.Keywords
This publication has 41 references indexed in Scilit:
- Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term SurvivalGastroenterology Research and Practice, 2012
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical TrialAnnals of Surgical Oncology, 2011
- Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal originJournal of Surgical Oncology, 2010
- Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal ChemotherapyAnnals of Surgical Oncology, 2010
- Epithelial Appendiceal NeoplasmsThe Cancer Journal, 2009
- Analysis of Prognostic Factors in Seventy Patients Having a Complete Cytoreduction plus Perioperative Intraperitoneal Chemotherapy for Carcinomatosis from Colorectal CancerJournal of the American College of Surgeons, 2006
- Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesotheliomaEuropean Journal of Surgical Oncology, 2006
- Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancerGynecologic Oncology, 2005
- Peritoneal carcinomatosis from colorectal cancerBritish Journal of Surgery, 2002
- Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal ChemotherapyAnnals of Surgery, 1995